Similarly, trials on adjunctive therapy with IFN-γ, which could also be used for MDR-TBM, have demonstrated that both aerosolized and intramuscular administration can significantly improve sputum negative conversion rates and chest radiograph outcomes in patients with pulmonary MDR-TB [51,52]. The gene discussed is IFNG; the disease is multidrug-resistant tuberculosis.